Drugs for the treatment of obesity have become one of the fastest-growing segments of the pharmaceutical industry. Denmark’s Novo Nordisk and U.S.-based Eli Lilly have built a significant part of their growth stories around them, but the battle for patients is far from over. Oral forms of treatment are entering the market, competitors are developing new active ingredients, and clinical trial results suggest that the next generation of drugs could offer more effective treatment options.
From Injections to Tablets
GLP-1 receptor agonists were originally used mainly to treat type 2 diabetes. Alongside regulating blood glucose, they affect hunger and satiety, helping to reduce body weight. This effect underpinned the development and approval of specific medicines for obesity. The best known include Ozempic and Wegovy from Denmark’s Novo Nordisk, and Mounjaro and Zepbound from U.S. company Eli Lilly. Although their mechanisms of action are related, these drugs differ in active ingredients, dosages and approved indications. A treatment once used mainly in medical care for patients with diabetes and obesity has gradually become a global phenomenon attracting celebrities and the general public, fundamentally reshaping competition in the pharmaceutical industry.
Tablets as the Next Stage
Tablet formulations may expand the pool of patients considering treatment. They are easier to take for people who prefer tablets over injections. That alone, however, guarantees neither greater efficacy nor better tolerability. Price, availability and patients’ ability to stay on treatment long term will also matter. In 2026, the tablet form of Wegovy received a positive regulatory opinion in the European Union and then marketing authorisation. Eli Lilly meanwhile introduced Foundayo, tablets containing the active ingredient orforglipron. The U.S. Food and Drug Administration (FDA) approved it in April 2026. In the EU, the Committee for Medicinal Products for Human Use (CHMP) recommended its authorisation for obesity and type 2 diabetes on October 15, 2026. By late October, however, the European Commission had not yet made a final decision.
The Battle Between Two Pharmaceutical Giants
Novo Nordisk and Eli Lilly are among the leading companies ‘benefiting’ from growing interest in obesity treatment. Their positions, however, can change. Eli Lilly posted approximately USD 23 billion in second-quarter 2026 revenue, up 48 percent year-on-year. The previously mentioned Mounjaro and Zepbound medicines contributed significantly. In August, the company raised its full-year revenue outlook to an expected USD 85–87 billion. Also in August 2026, Novo Nordisk improved its outlook for adjusted revenue and operating profit from a 4–12 percent decline to flat growth or a decline of up to 6 percent. Despite the improvement, it still expects both measures could fall year-on-year. This shows that even dominance in a growing market does not automatically ensure revenue and profit growth.[1]
The Next Generation of Players?
The competition is not just about who sells more of the existing medicines. Pharmaceutical companies are developing new active ingredients that could deliver greater weight loss, better blood sugar control or a different tolerability profile. Retatrutide, a molecule developed by Eli Lilly, is attracting considerable attention. The company is studying it in phase 3 clinical trials and has compared it with injectable Ozempic at a dose of 2 mg in adults with type 2 diabetes. After 80 weeks, average weight loss reached 19.5 percent with the 9 mg dose and 20.9 percent with the 12 mg dose. In the comparator group receiving Ozempic, it reached 9.4 percent. Another potential competitor is Viking Therapeutics, which is developing VK2735 in both injectable and oral forms. In October 2026, the company launched a phase 3 clinical trial programme for the tablet form. Petrelintide, being developed by Roche and Zealand Pharma, also deserves attention; in a phase 2 trial, it achieved average body weight loss of up to 10.7 percent after 42 weeks, compared with 1.7 percent with placebo. [2]
A Multibillion-Dollar Market, but Not Without Risks
Estimates for the growth of the global obesity drug market suggest that it could exceed USD 100 billion annually by 2030. However, the high cost of treatment may limit its use, especially if health insurers do not cover it or if reimbursement is subject to strict criteria. As competition increases, manufacturers may face pressure to lower prices, which could expand the number of patients while also affecting margins. The long-term sustainability of treatment is also important, as obesity is a chronic disease and weight may be regained after medication is discontinued. For investors, this means that demand for these drugs cannot be assessed separately from healthcare systems, regulatory decisions and long-term treatment outcomes. A growing number of patients creates an opportunity, but does not guarantee unlimited revenue growth. [3]
An Investment Opportunity or Excessive Expectations?
The obesity drug sector offers several investment opportunities. Oral medications may broaden the group of patients, while a new generation of active ingredients may provide additional treatment options. Large pharmaceutical companies benefit from existing products, distribution networks, manufacturing capacity and financial resources for further research. Smaller biotechnology companies, meanwhile, may introduce new active ingredients or different approaches to treatment. For companies such as Novo Nordisk and Eli Lilly, it is particularly important to monitor sales growth, prices, margins, competition and expectations for future earnings. For companies still developing new drugs, clinical trial results, regulatory decisions, the need for further financing and the probability of a commercial market launch play a greater role. [4]
[1,2,3,4] Forward-looking statements are based on assumptions and current expectations that may be inaccurate, or on the current economic environment, which may change. Such statements are not a guarantee of future performance. They involve risks and other uncertainties that are difficult to predict. Actual results may differ materially from those expressed or implied in any forward-looking statements.